What is cancer and how can we prevent it?

Highlights from BGICC 2020

PARP inhibitors and immunotherapy in ovarian cancer: From research to practice

CAR-T cell therapy for ALL: Current challenges and future approaches

Considerations for treatment sequencing in B-ALL

CART-T cell therapy in young patients with relapsed/refractory ALL

The role of blinatumomab followed by HSCT in paediatric patients with ALL

Defining the role of immunotherapy in B-cell ALL

BLAST: Blinatumomab for minimal residual disease in patients with ALL

Frontline therapy of ALL

BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL

Treatment of Ph-negative ALL in adolescents and young adults